title: Acute myeloid leukemia following 3M (mitoxantrone, mitomycin and methotrexate) chemotherapy for advanced breast cancer.
authors.forename: L M
authors.initials: LM
authors.lastname: Melillo
authors.forename: M R
authors.initials: MR
authors.lastname: Sajeva
authors.forename: P
authors.initials: P
authors.lastname: Musto
authors.forename: G
authors.initials: G
authors.lastname: Perla
authors.forename: N
authors.initials: N
authors.lastname: Cascavilla
authors.forename: M M
authors.initials: MM
authors.lastname: Minervini
authors.forename: G
authors.initials: G
authors.lastname: D'Arena
authors.forename: M
authors.initials: M
authors.lastname: Carotenuto
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D008937:Mitomycins / Q000009:adverse effects; D008942:Mitoxantrone / Q000009:adverse effects; D016609:Neoplasms, Second Primary / Q000139:chemically induced*
chemical_list: D008937:Mitomycins; D008942:Mitoxantrone; D008727:Methotrexate